Fig. 3

miR-615-3p promotes TGF-β1-induced breast cancer cell migration via enhancing Smad2 and Smad3 activation. a MDA-MB-231 cells were transfected with nonspecific control siRNA (Anti-NC) or miR-615-3p-targeted siRNA (Anti-miR-615-3p) and then treated with TGF-β1 (5 ng/ml) for the indicated periods of time. Whole-cell lysates were blotted with the indicated antibodies. Relative protein level listed in lower panel histogram of (a) was calculated and compared (Student’s t-test). b MCF-7 cells transfected with the control plasmid (NC) or miR-615-3p expression plasmid were treated with TGF-β1 (5 ng/ml) for 1 h. Whole-cell lysates were blotted with the indicated antibodies. Relative protein level listed in lower panel histogram of (b) was calculated and compared (Student’s t-test). c MDA-MB-231(left panel) cells were transfected with nonspecific control siRNA (Anti-NC) or miR-615-3p-targeted siRNA (Anti-miR-615-3p), MCF-7 cells (right panel) were transfected with control plasmid (NC) or miR-615-3p expression plasmid, underwent Transwell migration and invasion assays in the presence or absence of TGF-β1 (5 ng/ml). d MCF-7 cells transfected with the indicated reagents underwent Transwell migration and invasion assays in the presence or absence of SB431542 (10 μM). Columns show the mean of three independent experiments performed in triplicate. e MCF-7and MDA-MB-231 cells were transfected with indicated reagents, and whole-cell lysates were then blotted with the indicated antibodies. Relative protein level listed in right panel histogram of Fig. 3e was calculated and compared (Student’s t-test)